Business Bites: Medtronic wins major EU victory over Edwards, while Infuse cloud looms
This article was originally published in Clinica
Executive Summary
You win some, you lose some. And in the long-running patent wrangle between Medtronic and Edwards Lifesciences, bitter rivals in the transcatheter aortic valve implant (TAVI) market, it was definitely a victory for Medtronic when the European Patent Office this week invalidated in its entirety Edwards’ Spenser patent. This key patent was the basis for a prior injunction last year that prohibited Medtronic from selling its CoreValve system in Germany. Edwards is said to be appealing this judgement; in the meantime, this ruling removes a significant barrier for Medtronic and helps to buffer the blow it was dealt by the US court earlier this year. In January, a US federal jury found that Medtronic’s CoreValve wilfully infringed Edwards’ patents.
You may also be interested in...
Could Alcon's CyPass Trouble Be Boon For Glaukos – Or Bust For MIGS?
Minimally invasive glaucoma surgery specialist Glaukos saw its stock leap 40% in the wake of a worldwide recall by much bigger rival Alcon of its CyPass microstent.
Roche Dx' EMEA Head To Take Charge After Diggelmann Departs
Roland Diggelmann will end his decade-long career at Roche Diagnostics at the end of September. The business's head of EMEA Michael Heuer will take Diggelmann's place while the search is on for his replacement.
Nose For A Good Tech? Philips Adds Nasal Alar Pulse Oximetry To Monitoring Portfolio
Philips has added a new pulse oximetry platform to its patient monitoring portfolio, with the acquisition of Xhale Assurance.